Inimmune Confirms Mechanism of TLR4 Agonist INI-2004 in Allergic Rhinitis

Inimmune, a pioneering biotech firm, has announced promising pre-clinical data for its synthetic Toll-Like Receptor 4 (TLR4) agonist, INI-2004. The findings, which were published in Frontiers in Immunology on July 23, 2024, reveal that intranasal administration of INI-2004 can significantly alleviate allergy symptoms in a murine model of allergic sensitization. This innovative treatment method presents a notable advancement in addressing allergic diseases, showcasing both efficacy and safety.

INI-2004 operates as a fully synthetic, allergen-agnostic immunotherapy that targets and activates TLR4. In experiments involving mice with allergic rhinitis (AR), intranasal delivery of INI-2004 led to a marked decrease in airway resistance, eosinophil influx, and cytokines implicated in the pathogenesis of AR. These studies were fundamental to the development and success of a recently completed Phase 1a/b clinical trial (NCT06038279). The trial demonstrated that INI-2004 is not only safe and well tolerated over multiple administrations but also effective in reducing nasal congestion among individuals suffering from allergic rhinitis. This data underscores the value of using murine models to evaluate TLR4 agonists and provides proof of concept for the therapeutic potential of INI-2004.

Allergic rhinitis, which affects over 400 million people globally, is one of the most prevalent chronic diseases in the United States, impacting 10-30% of adults and 40% of children. Despite the high incidence, there remains an urgent need for safe and effective disease-modifying treatments. Dr. Jay Evans, Inimmune's Chief Scientific and Strategy Officer, emphasized the importance of addressing the root cause of allergic diseases. "Treating the underlying disease is a critical step in stopping the progression of atopy, especially for individuals sensitized to multiple allergens. We are thrilled about this novel treatment option for allergic rhinitis," Evans stated.

Inimmune Corporation, based in Missoula, Montana, is a privately held biotechnology company dedicated to developing cutting-edge immunotherapies, adjuvants, and vaccines. The company aims to harness the power of the human immune system to create safe and effective treatments for a range of conditions, including allergies, infectious diseases, autoimmune disorders, and cancer. Inimmune's research facilities are located within the Montana Technology Enterprise Center (MonTEC) in Missoula.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!